Aim: Thrombosis occurs in the coronary arteries via the activation of platelets, and leads to acute myocardial infarction and sudden death. Obovatol, a major biphenolic component of Magnolia obovata leaves, displays anti-inflammatory and acyl Co-A cholesterol acyltrasferase inhibitory effects. The purpose of this study was to determine the effects of obovatol on thrombus formation in vivo and platelet activation in vitro and ex vivo. Methods: We investigated the antiplatelet and antithrombotic activities of obovatol in rat carotid arterial thrombosis in vivo along with platelet aggregation in vitro and ex vivo. Its possible cellular mechanism of antiplatelet activity was investigated by testing PLC-2 activation, arachidonic acid cascade, calcium mobilization and granule secretion. Results: Oral administration of obovatol prevented carotid thrombosis, but also significantly inhibited collagen-induced platelet aggregation. Obovatol did not change coagulation times, such as activated partial thromboplastin time and prothrombin time, indicating that the antithrombotic effect of obovatol might be due to antiplatelet activity rather than anticoagulation activity. Obovatol inhibited in vitro collagen-and arachidonic acid-induced rabbit platelet aggregation in a concentration-dependent manner (1-10 M), with IC50 values of 2.4 0.8 and 4.8 0.9 M, respectively. Obovatol blocked collagen-mediated phospholipase C-2 phosphorylation, cytoplasmic calcium mobilization, arachidonic acid liberation and serotonin secretion. Conclusion: Obovatol has a potent antithrombotic effect, which may be due to antiplatelet activity. The antiplatelet activity of obovatol is mediated by inhibition of PLC-2 phosphorylation. Thus, obovatol may be a potential candidate to treat cardiovascular disease. J Atheroscler Thromb, 2011; 18:659-669.
Introduction
Once blood vessels become damaged, a diverse array of ligands, such as collagen, von Willebrand factor (vWF), ADP and thrombin, are generated at the injury site and induce platelet adhesion, followed by activation and aggregation 1) . Collagen enhances the adhesion of platelets to the injury site and induces platelet activation through a tyrosine kinase-based signaling pathway. Collagen activates the kinase Syk and phospholipase C-2 (PLC-2), and leads to increased cytoplasmic calcium, shape change and granule re-lease [2] [3] [4] [5] . Collagen-induced platelet activation results in platelet shape change and the release of substances that recruit activated platelets to the developing thrombus 6, 7) . When various inducers activate platelets, arachidonic acid is increased markedly via PLA2-mediated phospholipid hydrolysis 8, 9) . There are two main pathways of arachidonic acid metabolism in platelets. One is the cyclooxygenase (COX) pathway, which produces TXA2; the other is the 12-lipoxygenase (12-LOX) pathway, which produces 12-hydroxy-eicosatetraenoic acid (12-HETE). 12-HETE plays a positive feedback role in thrombus formation in vivo 10) and gives rise to platelet aggregation and aortic smooth muscle cell migration in vitro 11, 12) . 12-HETE and TXA2 appear to be involved in the initiation and propagation of thrombotic and atherosclerotic disorders. Although various arachidonic acid metabolites are produced from COX and LOX, TXA2 and 12-HETE activities play a major role in thrombosis 13) . Magnolia (Hou Po) was used medicinally as early as the first century and is a commonly prescribed Chinese traditional medicine. It possesses antioxidant activity approximately 1000 times greater than -tocopherol 14) . The biphenolic components from Magnolia obovata, including magnolol, honokiol and obovatol, exhibit antiplatelet 15) , antitumor 16) and antiinflammatory activities 17, 18) . In our ongoing search for antiplatelet agents from natural resources, we found that obovatol exhibited potent antiplatelet activity. In the study, we investigated the antiplatelet activity of obovatol by measuring in vitro and ex vivo agonist-induced platelet aggregation. Its possible cellular mechanism of antiplatelet activity was investigated by testing PLC-2 activation, arachidonic acid cascade, calcium mobilization and granule secretion. We also evaluated the antithrombotic activity of obovatol in the ferric chloride-induced arterial thrombosis model in rats.
Materials and Methods

Experimental animals
Male Sprague-Dawley rats were purchased from Dae-Han Biolink Co. (Eum sung, Korea) and acclimated for 1 week at 24 1 and 55 5% humidity. Male New Zealand white rabbits (n 8) were purchased from SamTako Bio Korea Inc. (Osan, Korea) and acclimated for at least 1 week at 24 1 and 55 5% humidity, with free access to drinking water and a commercial pellet diet obtained from SamTako Bio Korea Inc. before experiments. Animal experiments were carried out in accordance with the Guide for the Care and Use of Laboratory Animals, Chungbuk National University, Korea.
Arterial thrombus formation in vivo
The rat FeCl3 thrombosis model used for these studies was modified from that described 19) . Obovatol was orally administered to male Sprague-Dawley rats (240-260 g) daily at doses of 50 and 100 mg/kg for 3 days or carboxymethylcellulose (CMC) as a vehicle. The rats were anaesthetized with pentobarbital sodium salt (60 mg/kg, intraperitoneally). A segment of the right carotid artery was exposed and dissected free of the vagus nerve and surrounding tissues and then fitted on the Doppler flow probe (1 mm diameter). Blood flow was measured with a Doppler velocimeter (Crystal Biotech, Hopkinton, MA, USA). After 60-min administration of obovatol, thrombus was induced by placing a 2-mm 2 Whatman no. 1 filter paper saturated with 50% ferric chloride (FeCl3) on the carotid artery near the probe for 10 min. The time needed for occlusion to occur was measured for up to 60 min, and the occlusion time was assigned as a value of 60 min for vessels that did not occlude within 60 min.
Platelet aggregation and coagulation times assay ex vivo
Male Sprague-Dawley rats (240-260 g) were orally administered obovatol (50 and 100 mg/kg) for 3 days or CMC as a vehicle, and then blood was collected and platelet-rich plasma (PRP) was prepared by centrifuging the blood sample at 180 g for 10 min and platelet-poor plasma (PPP) was obtained by centrifuging the PRP at 2100 g for 10 min. PRP was adjusted to a density of 3 10 8 platelets/ml with PPP. Platelet aggregation was measured as previously described 20) using an aggregometer (Chrono-Log Co., Havertown, PA, USA). ADP (2 M) and collagen (10 g/ml) were used as agonists for platelet aggregation. Anticoagulation activity was evaluated by measuring plasma-clotting times. The plasma activated partial thromboplastin times (APTT) and prothrombin times (PT) were automatically measured using an Automated Coagulation Laboratory 100 Instrument (Instrumentation Laboratory Co., Milano, Italy).
Measurement of washed rabbit platelet preparation and aggregation
Rabbits were fixed in a cage. Blood was drawn from the ear artery of conscious rabbits and collected directly into Vacutainer tubes containing anticoagulant solution (composed of 0.8% citric acid, 2.2% trisodium citrate, and 2% dextrose (w/v)). PRP was prepared by centrifugation at 230 g for 10 min at room temperature. Platelets were sedimented by centrifugation of PRP at 2100 g for 10 min and then washed twice with HEPES buffer (137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 5.6 mM glucose, 0.35% bovine serum albumin, and 3.8 mM HEPES, pH 6.5) containing 0.4 mM EGTA. After centrifugation, the pellets were resuspended in HEPES buffer (pH 7.4). The platelet concentration was counted using a Coulter Counter (Coulter Electronics, Hialeah, FL, USA) and adjusted to 4 10 8 platelets per milliliter. Platelet aggregation was measured as previously described 20) . Briefly, washed platelet suspensions were incubated at 37 in the aggregometer with stirring at 1000 rpm. After incubation with various concentration of obovatol (1-10 M), DMSO (0.5%) as a control for 3 minutes, platelet aggregation was induced by the addition of collagen (10 g/mL), arachidonic acid (100 M), U46619 (1 M), thrombin (0.05 U/mL), respectively. The resulting aggregation measured as the change in light transmission was recorded for 10 min.
Measurement of thromboxane B2, prostaglandin D2 and 12-HETE
Thromboxane B2, prostaglandin D2 and 12-HETE generations were measured as previously described 20) . Briefly, washed rabbit platelets (4 10 8 platelets/mL) were preincubated with various concentrations of obovatol at 37 for 5 min and then further incubated with a mixture of [ 3 H]-AA (1 Ci/mL) and unlabeled AA (2 M) for 5 min. The reaction was terminated by the addition of stop solution (2.6 mM EGTA, 130 M BW755C, a dual COX and LOX inhibitor). Lipids were extracted and separated by silica gel G thin-layer chromatography (TLC) on silica gel G plates (Analtech, Newark, DE). The plates were developed in ethyl acetate/isooctane/acetic acid/H2O (9:5:2:10, v/v/ v/v). The area corresponding to each lipid standard was scraped off, and radioactivity was determined by a liquid scintillation counter (Beckman, Fullerton, CA, USA).
Measurement of arachidonic acid and diacylglycerol
Arachidonic acid liberation was measured as previously described 9) . In brief, PRP was preincubated with [ samples were then centrifuged at 2100 g at 4 for 10 min, and the upper phase was removed and evaporated to dryness under nitrogen. Residues were dissolved in chloroform/methanol (2:1, v/v) and applied to thin layer chromatography plates. The plates were developed in petroleum ether/diethyl ether/acetic acid (40:40:1, v/v/v). The area corresponding to arachidonic acid or diacylglycerol was scraped off, and radioactivity was determined.
Measurement of serotonin secretion
Serotonin concentration was determined by the fluorimetric method of Jin et al. 20) . Washed platelets were then pretreated with imipramine, serotonin reuptake inhibitor (5 M) and obovatol at 37 for 5 min, and collagen (10 g/mL) or arachidonic acid (100 M) was subsequently added. The reaction was stopped by the addition of 5 mM EDTA on ice, and then the supernatant was centrifuged at 12000 g for 2 min. The supernatant was mixed with 6 M trichloroacetic acid (TCA) and centrifuged at 12000 g for 2 min. A 0.6 mL aliquot of TCA supernatant was mixed with 2.4 mL of the solution (0.5% -phthalaldehyde in ethanol diluted 1:10 with 8 N HCl), placed in a boiling water bath for 10 min, and then cooled on ice. Excess lipids were extracted with chloroform, and the flurophore was measured at the excitation (360 nm) and emission (475 nm) wavelengths. Serotonin creatinine sulfate was used as a standard solution to calculate the extent of serotonin release.
Measurement of intracellular Ca
2 mobilization Cytoplasmic Ca 2 was measured as previously described 20) . In brief, rabbit platelets were incubated with 2 M Fura-2/AM at room temperature for 60 min in loading buffer (137 mM NaCl, 27 mM KCl, 0.4 mM NaH2PO4, 10 mM HEPES, 12 mM NaH-CO3, 5.5 mM dextrose, and 0.35% BSA, pH 7.4). Excess Fura-2/AM was removed by centrifugation and the platelets were suspended in fresh buffer without EGTA. Aliquots of platelet suspension (2.5 ml) were added to 4-ml cuvettes containing a Teflon-coated stir bar (Chrono-Log Co.). Just before [Ca 2 ]i was measured, Ca 2 was added back to the buffer to a final concentration of 1 mM, and then samples and agonists were added. The measurement of [Ca 2 ]i was performed at room temperature in an MSIII fluorometer (Photon Technology International, Monmouth Junction, NJ, USA) using excitation wavelengths of 340 and 380 nm and an emission wavelength of 505 nm. [Ca 2 ]i was calculated using the SPEX dM3000 software package.
Western blotting assay
For analysis of total platelet proteins, the reaction was terminated by the addition of Laemmli sample buffer, and the mixture was then boiled for 5 min and resolved by 7.5% SDS-PAGE. Western blotting assays were performed as previously described 21) . For Western blotting assays, proteins were electrically transferred to a polyvinylidene difluoride membrane for 80 min at 120 mA. Blots were incubated for 4 hours with 5% (w/v) BSA in TBS to block residual protein binding sites. Phospho-PLC-2 was detected by rabbit anti-phospho-PLC-2 antibody (Q-20, 1 g/mL) in TBS containing 5% BSA for 4 hours. The primary antibody was removed, and blots were washed three times in TBS with 0.05% Tween-20. Blots were incubated with alkaline phosphatase-conjugated anti-rabbit antibody (New England Biolabs, MA, USA) diluted to 1:5000 in TBS containing 5% BSA for 5 hours, and then washed five times in TBS with 0.05% Tween-20. They were exposed to hyper-film-enhanced chemiluminescence (Amersham Biosciences, Ltd., Buckinghamshire) for 5 min. The intensities of phospho-PLC-2 and total PLC-2 bands were quantified by Scion-Image for Windows (Scion Corporation, MA, USA).
Materials
The leaves of Magnolia obovata were harvested in Daejon, Korea, and identified by Dr. Byoung-Mog Kwon, Molecular Cancer Research Center, Korea Research Institute of Bioscience and Biotechnology. A voucher specimen was deposited in the same laboratory. Obovatol (Fig. 1) was isolated from Magnolia obovata leaves as described previously 22, 23) . Indomethacin, imipramine, serotonin creatinine sulfate and fura-2 acetoxymethyl ester (fura-2/AM) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). [ 3 H]-Arachidonic acid (220 Ci/mmol) was obtained from Perkin-Elmer Life and Analytical Sciences (Boston, MA, USA). Collagen, arachidonic acid and thrombin were purchased from Chrono-Log Co. U46619 (9,11-dideoxy-9 ,11 -methanoepoxyprostaglandin F2 ), TXB2, PGD2 and 12-HETE were purchased from Cayman Chemical Co. (Ann Arbor, MI, USA). Anti-PLC-2 and anti-phospho-PLC-2 (Q-20) antibodies were obtained from Upstate Biotechnology Inc. (Lake Placid, NY, USA). All other chemicals were of analytical grade.
Isolation and purification of obovatol from
Magnolia obovata
The leaves of Magnolia obovata were harvested in Daejeon, Korea and the isolation procedure of the active compound was the same as reported previously 23) .
The dried and milled sample (1 kg) was soaked in chloroform/acetone (1:1, v/v, 5 L) at room temperature for 5 days. The extract was concentrated under reduced pressure and purified by silica gel, C18 column chromatography and preparative thin layer chromatography (TLC). Finally, we purified the active compound by high-performance liquid chromatography (HPLC) (Phenomenex, Ultracarb 10ODS; 250 21.2 mm at 285 nm, flow rate 3.5 mL/min) using a linear gradient rising from 80 to 90% methanol for 50 min. The tR in HPLC of active compound (120 mg) was 35 min. The mass spectroscopic, infra-red spectroscopic and nuclear magnetic resonance data for the purified compound were in good agreement with the spectral data for obovatol (C18H18O3, mol. Wt 282 kDa) (Fig. 1) .
Statistical analysis
The experimental results are expressed as the means S.E.M. One-way analysis of variance (ANO-VA) was used for multiple comparisons (GraphPad Prism version 4.00 for Windows; San Diego, CA, USA). If there was a significant variation between treated groups, the Dunnett test was applied. The data were considered significant when P 0.05.
Results
Extension of time to arterial thrombus formation
To investigate the effects of obovatol on pathologic and occlusive thrombus formation in vivo, rat carotid artery thrombus was induced by FeCl3 3 days after oral administration of obovatol or carboxymethylcellulose as a vehicle control. The injured vessels were occluded within 12.8 1.3 min in the control group. After oral administration of obovatol to rats, the occlusion times were significantly prolonged to 22.4 5.4 and 31.6 6.4 min at doses of 50 and 100 mg/kg body weight (P 0.01, n 10), respectively (Fig. 2) . Obovatol-treated groups at 50 and 100 mg/ kg showed prolongation of the thrombus time by 1.8-and 2.5-fold, respectively, compared to the control.
Inhibition of ex vivo platelet aggregation
To distinguish whether the antithrombotic effect of obovatol was due to the inhibition of either platelet aggregation or coagulation activity, they were examined after oral administration of obovatol at 50 and 100 mg/kg to rats. Obovatol significantly inhibited collagen-induced platelet aggregation by 39.5 4.5 and 94.9 1.6% (P 0.01, n 7) at doses of 50 and 100 mg/kg body weight, respectively; however, obova-tol failed to inhibit ADP-induced platelet aggregation (Fig. 3A) . The APTT and PT in the control group were 23.2 0.9 and 18.8 0.3 sec, respectively; however, APTT and PT in obovatol-treated groups were 22.6 0.7 and 19.4 0.2 sec at a dose of 50 mg/kg, and 22.8 1.6 and 18.7 0.3 sec at a dose of 100 mg/ kg, respectively. Thus, these results suggest that obovatol does not change coagulation times (Fig. 3B) .
Washed rabbit platelet aggregation in vitro
Obovatol inhibited collagen-(10 g/mL) and arachidonic acid (100 M) -challenged washed rabbit platelet aggregation in a concentration-dependent manner, with IC50 values of 2.4 0.8 and 4.8 0.9 M, 
. Extension of arterial thrombus formation time in vivo
Rat carotid artery was subjected to chemical injury by placing a 2-mm 2 Whatman no.1 filter paper saturated with 50 % FeCl3 on the carotid artery for 10 min, and then blood flow was measured with a Doppler velocimeter. Obovatol (50 and 100 mg/kg) was orally administered for 3 days, and the results are expressed as the occlusion time (n 10). Significantly different from control at P 0.01.
Fig. 3. Effect of obovatol on platelet aggregation and coagulation times ex vivo
Obovatol (50 and 100 mg/kg) was orally administered for 3 days, and blood was collected 60 min after the last treatment. In the ex vivo platelet aggregation assay, PRP was obtained by centrifugation blood samples at 180 g for 10 min. Platelet aggregation was induced by collagen (10 g/mL) or ADP (2 M) (A). In the coagulation assay, PPP was obtained by centrifuged at 2100 g for 10 min, and then APTT and PT were measured as described in Materials and Methods. Data (mean S.E.M.) are from seven animals in each group. Significantly different from control at p 0.01.
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respectively (Fig. 4) . However, obovatol had no effect on U46619-(1 M) and thrombin (0.05 U/mL) -induced platelet aggregation, which indicates that obovatol may be involved in the inhibition of collagenmediated platelet aggregation. In addition, platelet viability was determined by a MTT assay in order to exclude the possibility that the antiplatelet activity of obovatol was related to cytotoxity. Obovatol did not affect platelet viability compared with the control at concentrations of up to 50 M (date not shown).
Inhibition of arachidonic acid metabolism
In order to examine the effect of obovatol on the arachidonic acid metabolism pathways, washed rabbit platelets were preincubated with obovatol (5, 10 µM) and then further incubated with a mixture of [ (Fig. 5) . TXB2 production of obovatol at concentrations of 5 and 10 M was inhibited by 80.8 and 86.9% (Fig. 5A) , PGD2 generation by 49.3 and 61.2% (Fig. 5B) and 12-HETE production by 72.3 and 74.4% (Fig. 5C) , respectively. The inhibition of TXB2 formation by obovatol occurred at a much lower concentration, 5 M, than by aspirin, a positive control, 50 M, suggesting that obovatol may be a potent inhibition of TXB2 formation. (Fig. 6A) . Collagen-induced diacylglycerol formation of rabbit platelets was inhibited by obovatol (Fig. 6B) . Inhibition by 1, 3 and 10 M obovatol of the diacylglycerol liberation component to the concurrent controls was 16.7, 60.3 and 71.1%, respectively. U73122, a phospholipase C inhibitor, was used at 50 M as a positive control and blocked the liberation of arachidonic acid and diacylglycerol. Obovatol at 1, 3 and 10 M reduced the collagen-induced secretion of serotonin in a concentration-dependent manner by 30.4, 56.4 and 86.6%, respectively (Fig. 6C) . Obovatol at 1, 5 and 10 M also decreased the arachidonic acid-induced secretion of serotonin by 11.9, 22.1 and 70.9%, respectively (Fig. 6D) .
Inhibitory effect of obovatol on cytoplasmic calcium mobilization
PLC catalyzes the simultaneously liberation of diacylglycerol and IP3, which induces calcium release from the dense tubular system leading to platelet aggregation. Cytosolic calcium mobilization is very important in collage-mediated platelet aggregation and depends on the cytosol levels of IP3. We hypothesized that obovatol may affect cytosolic calcium mobilization. Collagen-and arachidonic acid-induced cytosolic calcium mobilization was completely blocked by obovatol at 10 M. These observations well correlated with the results of platelet aggregation (Fig. 7) . 3 H]-arachidonic acid-labeled platelets. After platelet suspensions were incubated with obovatol (1-10 M) or with U73122 (50 M), a PLC inhibitor, in the presence of 100 M BW755C, the platelets were stimulated with 10 g/mL collagen for 2 min. Washed rabbit platelet suspension was incubated with imipramine (5 M), a serotonin reuptake inhibitor, and obovatol (1-10 M) at 37 for 5 min prior to the addition of (C) collagen (10 g/mL) or (D) arachidonic acid (100 M). The serotonin concentration was determined by a fluorimetric method. Data are expressed as the means S.E.M. (n 3). Significantly different from the control at P 0.05, P 0.01.
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In h i b i t o r y e f f e c t o f o b ov a t o l o n P LC -2 phosphorylation
Obovatol inhibited collagen-induced diacylglycerol formation and cytoplasmic calcium mobilization in rabbit platelets. Thus, we investigated the expression of PLC-2, an upstream component of collageninduced platelet aggregation, to determine whether PLC-2 may be a target for obovatol inhibition of platelet aggregation. Washed rabbit platelets were stimulated with 10 g/mL collagen in the presence or absence of obovatol, and PLC-2 phosphorylation levels were examined. Pretreatment with obovatol at concentrations of 1, 3 and 10 M significantly inhibited collagen-induced PLC-2 phosphorylation with inhibition percentages of 28.2, 47.2 and 96.6%, respectively (Fig. 8) .
Discussion
Thrombosis occurs in the coronary arteries via the activation of platelets, and leads to acute myocardial infarction and sudden death 19) . In the present study, we demonstrated that obovatol had antithrombotic and antiplatelet activities. In the rat artery thrombosis model, ferric chloride caused oxidative arterial injury and exposed the subendothelial matrix. Platelets interact with collagen and von Willebrand factor (vWF) in the matrix via platelet membrane GPIb-V-IX and IIb 3. In platelets, glycoprotein VI binding to collagen leads to platelet activation, fol- [2] [3] [4] . Calcium mobilization is a major cellular process in collagen-mediated platelet activation and is mainly IP3-dependent 33) . Collagen-and arachidonic acid-induced cytoplasmic calcium mobilization was completely blocked by obovatol (Fig. 7) . Therefore, we hypothesized that obovatol may also affect cytoplasmic calcium mobilization based on the inhibition of collagen-induced diacylglycerol formation and presumably the elevation of IP3. Inhibition of calcium mobilization by obovatol in platelets was well correlated with the inhibition of platelet aggregation, and serotonin secretion from the dense tubular system in a concentration-dependent manner (Fig. 6C and D) .
Collagen-mediated cytoplasmic calcium mobilization results from the activation of PLC-2 to generate IP3 7) . Obovatol inhibited the collagen-induced phosphorylation of PLC-2 in a similar concentration range with the inhibition of platelet aggregation (Fig. 8) . These results suggest that inhibition of PLC-2 phosphorylation by obovatol may be responsible for the inhibition of collagen-mediated platelet aggregation. The intracellular target of obovatol in the collagen-mediated signaling transduction pathway remains unknown. Obovatol had no effect on thrombin-induced platelet aggregation, while U73122, a PLC inhibitor, inhibited both collagen and thrombininduced platelet aggregation (data not shown). Thus, it is reasonable to speculate that the potential target for obovatol may be involved in prior inhibition of the upstream signal(s) of PLC-2 rather than direct inhibition of PLC, as obovatol had no effect on thrombinor U46619-induced platelet aggregation. The upstream component of PLC includes collagen receptor and tyrosine kinase, which may be a potential target of obovatol. Future studies of obovatol-induced inhibition of platelet aggregation need to be pursued. The inhibition of tyrosine kinase by obovatol may also contribute to the inhibition of collagen-induced platelet aggregation, as polyphenols have been reported to exhibit such inhibitions on tyrosine kinase [34] [35] [36] . Further study of this issue is still needed.
Taken together, obovatol significantly protection against artery thrombosis in vivo, which may be due to antiplatelet activity. In addition, obovatol inhibited platelet aggregation induced by collagen and arachidonic acid, and the cellular mechanism of the antiplatelet activity of obovatol appears to be mainly mediated by the inhibition of PLC-2 phosphorylation. This beneficial property of obovatol may be important in improving thrombosis because platelet aggregation is an important determinant of thrombus initiation and development, and obovatol may contribute to the treatment of cardiovascular diseases. lowed by calcium mobilization, the release of ADP and TXA2, platelet recruitment and activation and thrombus formation 24) . Thus, platelet aggregation contributes to thrombus formation. Oral administration of obovatol significantly increased the occlusion time (Fig. 2) , which indirectly indicated that obovatol was able to inhibit thrombus formation in vivo via the inhibition of platelet aggregation, because obovatol did not prolong APTT or PT (Fig. 3B) . The exact mechanism by which thrombus formation is triggered in this model is not clear, but it has been shown that the morphology of the thrombi is similar to in humans 25) . Thus, the antithrombotic effect of obovatol on the ferric chloride-mediated rat artery thrombosis model may be due to its antiplatelet activity, rather than anticoagulation activity 26) . vWF plays an important role in platelet adhesion and thrombus formation. vWF binds to the platelet membrane GPIb-IX-V and initiates signals leading to platelet activation 27) . These events were promoted by the action of TXA2 produced from arachidonic acid. TXA2 has proaggregatory and vasoconstrictor properties that amplify the initiating stimulus and contribute to platelet plug formation 28) . Arachidonic acid released from platelets is metabolized to TXA2 on the COX pathway followed by PLC activation, an increase in [Ca 2 ]i and protein kinase C activation 29, 30) . For this reason, the arachidonic acid-mediated pathway plays a central role in platelet activation by vWF. Collagen adheres to platelets, leading to platelet shape change, and the release of serotonin and TXA2 from dense granules. Obovatol potently inhibited collagen-and arachidonic acid-induced washed rabbit platelet aggregation (Fig. 4) . In platelets, arachidonic acid is further metabolized either to TXA2 and PGs through the COX pathway or to 12-HETE through the LOX pathway 31) . Obovatol inhibited the biosynthesis of both TXA2 and PGD2, and suppressed 12-HETE generation induced by arachidonic acid in platelets (Fig. 5) , indicating that the release of arachidonic acid is suppressed by obovatol, thereby inhibiting the production of TXA2, PDG2 and 12-HETE.
Diacylglycerol and IP3 are produced from membrane phospholipids by PLC-2 after stimulation with collagen. Diacylglycerol activates platelets via protein kinase C with the activation of integrin IIb 3 32) . Obovatol inhibited collagen-stimulated arachidonic acid liberation and diacylglycerol formation (Fig. 6) . It has been reported that collagen induces platelet activation through a tyrosine kinase-based signaling pathway that includes Syk and PLC-2 7) , leading to [Ca 2 ]i increase, platelet shape change and dense granule release, adhesion and platelet aggrega-
